Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (including IBS without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by altered bowel motility, stool consistency, and frequency, and is classified into constipation-predominant, diarrhea-predominant, and mixed subtypes. This analysis focuses on constipation-predominant IBS (IBS-C) and IBS without diarrhea. Treatment options for IBS-C are limited, with few FDA-approved therapies. Current management includes off-label agents such as antidepressants, motor stimulants, anticholinergic agents, and approved therapies including guanylate cyclase-C agonists (Linzess and Trulance), bicyclic fatty acids (Amitiza and generic lubiprostone), and NHE3 inhibitor Ibsrela.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IBS-C patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-C patients?
- How has Linzess been integrated into the treatment algorithm, and what is its source of business?
- What percentage of IBS-C patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of IBS-C patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Linzess, Ibsrela, Trulance, Amitiza, lubiprostone (generic), SSRIs, Tricyclic agents, Anticholinergics
Key analyses: Brand / therapy usage across patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flow charts
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
